Dosage Forms – Talk Bio

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

2 days ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001

4 weeks ago talkbio0Tagged Alumis, Dermatology field, Dosage Forms, ESK-001, Inhibitor, Japan, Kaken, licensing agreement, TYK2 gene

Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan

Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal

1 month ago talkbio0Tagged Dosage Forms, licensing agreement, Polycythemia, RNA-targeted medicine, Sapablursen, vera

Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine

Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront

2 months ago talkbio0Tagged chronic, Dosage Forms, KRP, KRP-M223, Kyorin, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, chronic spontaneous urticaria, licensing deal, MRGPRX2 antagonist

Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases

2 months ago talkbio0Tagged Antagonist muscle action, chronic, Dosage Forms, Dupixent, KRP, KRP-M223, Kyorin, licensing agreement, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

2 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

FDA Approves Ono Pharmaceutical’s Romvimza for Rare Joint Tumor

2 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, Deciphera acquisition, Dosage Forms, Fibrous histiocytoma of tendon sheath, Infrequent, Romvimza, tenosynovial, United States Food and Drug Administration

Romvimza, tenosynovial giant cell tumor (TGCT), FDA approval, Ono Pharmaceutical, Deciphera acquisition, kinase inhibitor, rare cancer treatment

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

2 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections

2 months ago talkbio0Tagged alpha 1-antitrypsin, Chengdu, Chinese Language, Dosage Forms, Failed, import alert, innovation, Inspection (procedure), manufacturers, Quality, Science of Chemistry, United States Food and Drug Administration, Wuhu

FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

2 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs